• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


1.306 EUR 0.074 6.01%

As of 12:03:14 ET on 10/24/2014.

Snapshot for Exelixis Inc (EX9)

Open: 1.271 Day's Range: 1.239 - 1.306 Volume: 100
Previous Close: 1.232 52wk Range: 1.073 - 6.152 1-Yr Rtn: -65.97%

Stock Chart for EX9

No chart data available.
  • EX9:GR 1.306
  • 1D
  • 1M
  • 1Y
Interactive EX9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for EX9

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -1.5310
Est. PEG Ratio -
Market Cap (M EUR) 254.81
Shares Outstanding (M) 195.11
30 Day Average Volume 8,360
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/04/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for EX9

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for EX9

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.

Michael M MorrisseyPresident/CEOJ Scott GarlandExec VP/Chief Commercial Ofcr
Jeffrey J HessekielExec VP/General CounselGisela M SchwabExec VP/Chief Medical Officer
More Company Profile & Key Executives for EX9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil